Nat Commun:蒸汽喷射打印--解决多病者吃药痛苦新策略!

2017-09-30 36氪 药物传递系统

吃药是一个痛苦的事情。最痛苦的事情还不在于药片的苦,而在于,一下子吃很多种药(比如说七八种)的话,拿这个药片那个胶囊的,很麻烦,如果上班的话,带着一堆药瓶子去公司,就更麻烦,时间一久,光吃药的麻烦劲儿就会让人厌倦,所以病没全好,有时候就把药停了。


吃药是一个痛苦的事情。最痛苦的事情还不在于药片的苦,而在于,一下子吃很多种药(比如说七八种)的话,拿这个药片那个胶囊的,很麻烦,如果上班的话,带着一堆药瓶子去公司,就更麻烦,时间一久,光吃药的麻烦劲儿就会让人厌倦,所以病没全好,有时候就把药停了。

从小体弱多病的我,在这一点上深有感触。

基于这种多病属性,密歇根大学研究人员开发的一种新技术,引起了我的兴趣。这种技术可以将多种药物打印在一次性的条装带或者贴片上,就像糖果纸那样。这项成果已经发表在《自然》的子刊《自然—通信》上。

在测试中,这些药物和传统的药物一样有效,可以破坏培养的癌细胞。关键的是,这种技术同时打印多种药物,对于每天服用很多处方药的患者来说,这要方便得多。

把需要吃的药打印到一张贴片上,一饮而尽,确实比来回开药瓶子要简洁很多,而且,去公司的话,不用带一堆药瓶子随身,这一点对上班族来说有更大的实用性。

这种技术的初衷本身也是如此:希望提高患者的依从性,老老实实地遵医嘱把该吃的药按时按量吃了。对于小孩来说,有了这种技术,给他们喂药的麻烦也要减少很多。

此外,它可以让药品更容易被运送到困难的地区,比如战区或农村地区,因为有些药品按照常规保存方法,在运输过程中很难让它们保持稳定。

而大肆宣传的个性化医疗也要求有一种简单、低成本、本地化的方式,来生产针对个人的少量物质。

据 engadget 报道,密歇根大学的 Max Shtein 教授介绍道:“医生或药剂师可以选择任何数量的药物,这台机器会把他们结合在一起。这台机器可以放在药店的后面,甚至是在诊所里。”

因此,理论上说,这种技术也拥有个性化医疗的应用前景。

研究人员使用了“蒸汽喷射打印”(vapor jet printing)技术,来开发他们的新药物制造技术。这使得高分辨率的打印,能够被精确地打印到一个精细的晶体结构上。

具体来说,在这种技术中,活性成分被蒸发掉,然后再与一股像氮气这样样的惰性气体混合在一起。随后,药物会随气体一起传播,然后在冷却的表面凝结成一层薄薄的结晶膜。

这种排列会使得药物的溶解变得更加容易。

Shtein 说:“制药公司拥有数以百万计的化合物来评估,第一个测试便是溶解度。大约有一半的新化合物没有通过这项测试,并且被排除在外。有机蒸汽喷射打印可以使其中一些更容易溶解。”

当然,这项技术还需要数年时间,才能打印出面向大众的药物。

不过,短期内,它可能会开始在制药公司内部使用,这些公司可以利用这种贴片技术,快速药物生产来加速临床试验。

密歇根大学医学院的教授、论文的合作者 Gregory Amidon 表示:“制药公司面临的主要挑战之一是对人类临床测试的速度,这项技术为加快新药的评估提供了一种新的方法。”

但是研究人员希望,有一天,这项技术可以在像糖果纸一样的卷纸上打印大量的药物。

不过,还是祝愿大家、也祝愿我自己远离疾病吧。就我个人经验来说,生病这种事,只能是病好了之后给别人提供段子,让大家开心一下,可是这种生产段子的方式效率太低了,费时费力折磨身体还花钱,实在犯不上。看别人倒霉也一样可以创造段子嘛,为什么非要自己倒霉呢,对吧?

所以,还是健健康康地活着吧,身体倍儿棒,呼吸吐纳之间,感觉风清月朗、碧海长空,挺好。

原始出处:

Olga Shalev, Shreya Raghavan, J. Maxwell Mazzara, et al.Printing of small molecular medicines from the vapor phase.Nature Communications 8, Article number: 711 (2017) doi:10.1038/s41467-017-00763-6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882483, encodeId=08ff18824837a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 13 14:57:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087138, encodeId=a3e3208e13834, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Nov 25 22:57:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478406, encodeId=299214e840632, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon Oct 02 00:57:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249101, encodeId=044e249101ab, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:25:19 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249098, encodeId=60ff24909861, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:23:37 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
    2018-03-13 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882483, encodeId=08ff18824837a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 13 14:57:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087138, encodeId=a3e3208e13834, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Nov 25 22:57:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478406, encodeId=299214e840632, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon Oct 02 00:57:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249101, encodeId=044e249101ab, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:25:19 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249098, encodeId=60ff24909861, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:23:37 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
    2017-11-25 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882483, encodeId=08ff18824837a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 13 14:57:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087138, encodeId=a3e3208e13834, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Nov 25 22:57:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478406, encodeId=299214e840632, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon Oct 02 00:57:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249101, encodeId=044e249101ab, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:25:19 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249098, encodeId=60ff24909861, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:23:37 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882483, encodeId=08ff18824837a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 13 14:57:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087138, encodeId=a3e3208e13834, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Nov 25 22:57:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478406, encodeId=299214e840632, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon Oct 02 00:57:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249101, encodeId=044e249101ab, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:25:19 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249098, encodeId=60ff24909861, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:23:37 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
    2017-09-30 1ddf0692m34(暂无匿称)

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1882483, encodeId=08ff18824837a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 13 14:57:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087138, encodeId=a3e3208e13834, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Nov 25 22:57:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478406, encodeId=299214e840632, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon Oct 02 00:57:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249101, encodeId=044e249101ab, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:25:19 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249098, encodeId=60ff24909861, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Sep 30 12:23:37 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
    2017-09-30 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0